Table 1.
Baseline Characteristics of Women With New Back Pain Suggestive of a Possible Clinical VFx
| Characteristic | No clinical VFx | Clinical VFx | ||
|---|---|---|---|---|
| Romosozumab 210 mg QM | Placebo | Romosozumab 210 mg QM | Placebo | |
| N = 44 | N = 55 | N = 3 | N = 17 | |
| Age, mean (SD), years | 70.2 (6.7) | 71.1 (7.2) | 73.3 (4.5) | 72.1 (7.4) |
| BMD LS T‐score, mean (SD) | −2.84 (1.0) | −2.86 (1.0) | −3.25 (0.6) | −3.17 (1.1) |
| BMD total hip T‐score, mean (SD) | −2.62 (0.4) | −2.59 (0.4) | −1.75 (0.6) | −2.58 (0.5) |
| BMD femoral neck T‐score, mean (SD) | −2.74 (0.32) | −2.78 (0.32) | −2.62 (0.10) | −2.77 (0.32) |
| Prevalent VFx, n (%) | 10 (22.7) | 12 (21.8) | 2 (66.7) | 3 (17.7) |
| Prior non‐VFx at or after age 55 years, n (%) | 11 (25.0) | 17 (30.9) | 1 (33.3) | 6 (35.3) |
| FRAX score (10‐year probability of major osteoporotic fracture), median (range) | 11.0 | 13.6 | 10.3 | 16.5 |
| (4.4 to 29.4) | (4.4 to 48.9) | (7.7 to 15.4) | (4.5 to 46.2) | |
| FRAX score (10‐year probability of hip fracture), median (range) | 4.4 | 6.5 | 3.7 | 7.7 |
| (1.6 to 12.0) | (1.4 to 34.2) | (2.9 to 5.1) | (1.5 to 35.6) | |
LS = lumbar spine; QM = per month; VFx = vertebral fracture; FRAX = fracture risk assessment tool.